Rachel E Climie1,2,3, Thomas T van Sloten4,5, Marie-Cécile Périer4, Muriel Tafflet4, Aurore Fayosse6, Aline Dugravot6, Archana Singh-Manoux6,7, Jean-Philippe Empana4. 1. Université de Paris, INSERM U970, Paris Cardiovascular Research Centre (PARCC), Integrative Epidemiology of Cardiovascular Disease Team, Paris, France rachel.climie@inserm.fr. 2. Baker Heart and Diabetes Institute, Melbourne, Australia. 3. Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia. 4. Université de Paris, INSERM U970, Paris Cardiovascular Research Centre (PARCC), Integrative Epidemiology of Cardiovascular Disease Team, Paris, France. 5. Cardiovascular Research Institute Maastricht and Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands. 6. Université de Paris, INSERM U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Paris, France. 7. Department of Epidemiology and Public Health, University College, London, U.K.
Abstract
OBJECTIVE: Most previous studies on cardiovascular health (CVH) and incident type 2 diabetes (T2D) have used a single measure of CVH, and none have investigated the association with impaired fasting glucose (IFG). We examined the association between changes in CVH and incident T2D and IFG. RESEARCH DESIGN AND METHODS: Within the Whitehall II study, CVH was examined every 5 years from 1991/93 until 2015/16. Subjects with 0-2, 3-4, and 5-6 ideal metrics of CVH from the American Heart Association were categorized as having low, moderate, or high CVH, respectively. RESULTS: There were 6,234 participants (mean age 49.8 ± 6.0 years, 70% male) without prior cardiovascular disease and T2D, including 5,015 who were additionally free from IFG at baseline. Over a median follow-up of 24.8 (interquartile range 24.0-25.2) years, 895 and 1,703 incident cases of T2D and IFG occurred, respectively. Change in CVH between 1991/93 and 2002/04 was calculated among 4,464 participants free from CVD and T2D and among 2,795 participants additionally free from IFG. In multivariate analysis, compared with those with stable low CVH, risk of T2D was lower in those with initially high CVH (hazard ratio [HR] 0.21; 95% CI 0.09, 0.51), those who had persistently moderate CVH or changed from moderate to high CVH (moderate-moderate/high; HR 0.53; 95% CI 0.41, 0.69), low-moderate/high (HR 0.62; 95% CI 0.45, 0.86), and moderate-low (HR 0.74; 95% CI 0.56, 0.98). Results were similar for IFG, but the effect sizes were smaller. CONCLUSIONS: Compared with stable low CVH, other patterns of change in CVH were associated with lower risk of T2D and IFG.
OBJECTIVE: Most previous studies on cardiovascular health (CVH) and incident type 2 diabetes (T2D) have used a single measure of CVH, and none have investigated the association with impaired fasting glucose (IFG). We examined the association between changes in CVH and incident T2D and IFG. RESEARCH DESIGN AND METHODS: Within the Whitehall II study, CVH was examined every 5 years from 1991/93 until 2015/16. Subjects with 0-2, 3-4, and 5-6 ideal metrics of CVH from the American Heart Association were categorized as having low, moderate, or high CVH, respectively. RESULTS: There were 6,234 participants (mean age 49.8 ± 6.0 years, 70% male) without prior cardiovascular disease and T2D, including 5,015 who were additionally free from IFG at baseline. Over a median follow-up of 24.8 (interquartile range 24.0-25.2) years, 895 and 1,703 incident cases of T2D and IFG occurred, respectively. Change in CVH between 1991/93 and 2002/04 was calculated among 4,464 participants free from CVD and T2D and among 2,795 participants additionally free from IFG. In multivariate analysis, compared with those with stable low CVH, risk of T2D was lower in those with initially high CVH (hazard ratio [HR] 0.21; 95% CI 0.09, 0.51), those who had persistently moderate CVH or changed from moderate to high CVH (moderate-moderate/high; HR 0.53; 95% CI 0.41, 0.69), low-moderate/high (HR 0.62; 95% CI 0.45, 0.86), and moderate-low (HR 0.74; 95% CI 0.56, 0.98). Results were similar for IFG, but the effect sizes were smaller. CONCLUSIONS: Compared with stable low CVH, other patterns of change in CVH were associated with lower risk of T2D and IFG.
Authors: Aaron R Folsom; Hiroshi Yatsuya; Jennifer A Nettleton; Pamela L Lutsey; Mary Cushman; Wayne D Rosamond Journal: J Am Coll Cardiol Date: 2011-04-19 Impact factor: 24.094
Authors: Donald M Lloyd-Jones; Yuling Hong; Darwin Labarthe; Dariush Mozaffarian; Lawrence J Appel; Linda Van Horn; Kurt Greenlund; Stephen Daniels; Graham Nichol; Gordon F Tomaselli; Donna K Arnett; Gregg C Fonarow; P Michael Ho; Michael S Lauer; Frederick A Masoudi; Rose Marie Robertson; Véronique Roger; Lee H Schwamm; Paul Sorlie; Clyde W Yancy; Wayne D Rosamond Journal: Circulation Date: 2010-01-20 Impact factor: 29.690
Authors: Joshua J Joseph; Justin B Echouffo-Tcheugui; Mercedes R Carnethon; Alain G Bertoni; Christina M Shay; Haitham M Ahmed; Roger S Blumenthal; Mary Cushman; Sherita H Golden Journal: Diabetologia Date: 2016-06-08 Impact factor: 10.122
Authors: Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte Journal: Lancet Date: 2009-06-08 Impact factor: 79.321
Authors: M G Marmot; G D Smith; S Stansfeld; C Patel; F North; J Head; I White; E Brunner; A Feeney Journal: Lancet Date: 1991-06-08 Impact factor: 79.321
Authors: Lisa S Chow; Andrew O Odegaard; Tyler A Bosch; Anne E Bantle; Qi Wang; John Hughes; Mercedes Carnethon; Katherine H Ingram; Nefertiti Durant; Cora E Lewis; Justin Ryder; Christina M Shay; Aaron S Kelly; Pamela J Schreiner Journal: Diabetologia Date: 2016-05-16 Impact factor: 10.460
Authors: Anne E Bantle; Lisa S Chow; Lyn M Steffen; Qi Wang; John Hughes; Nefertiti H Durant; Katherine H Ingram; Jared P Reis; Pamela J Schreiner Journal: BMJ Open Diabetes Res Care Date: 2016-08-31